Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision individualized biologic therapy with or without methotrexate for psoriasis
ChiCTR2400087931Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate, secukinumab, ixekizumab, ustekinumab, guselkumab and 1 more in plaque psoriasis (10 arms), sponsored by Huashan Hospital. Primary endpoint: Clinical efficacy. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
methotrexatesecukinumabixekizumabustekinumabguselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400087931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087931.